Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.
Actively Recruiting
Researchers are studying finerenone to find a better long-term treatment for children and young adults with heart failure and left ventricular systolic dysfunction LVSD, a condition where the hearts left side is weak and cannot pump blood well. The study aims to understand how safe finerenone is and how well it works when added to standard heart failure treatments in participants from newborns up to 18 years old. Participants will receive finerenone treatment for up to 9 months while continuing their usual heart failure care. The study includes children and young adults who joined an earlier finerenone trial and newly enrolled newborns under 6 months old with LVSD. Participants will attend at least six visits during the treatment period, where various health checks and tests will be done. During the study visits, researchers will measure vital signs, take blood samples, perform heart tests like electrocardiograms and echocardiograms, and ask about medication use and any medical problems. Parents or guardians of newborns and infants will provide feedback on how acceptable the study drug formulation is. After finishing treatment, participants will have a follow-up health check about one month later. The study will monitor safety by tracking medical problems and changes in potassium levels, blood pressure, and kidney function.
Actively Recruiting
Researchers are evaluating a new way to treat children aged 1 to 18 years with chronic kidney disease CKD and proteinuria, a condition where kidneys leak protein into the urine. The study focuses on adding finerenone to existing treatments of angiotensin-converting enzyme inhibitors ACEI or angiotensin receptor blockers ARB, which are commonly used to control blood pressure and protect kidney function. The goal is to understand the long-term safety of finerenone combined with these standard treatments, as well as its effect on kidney health and protein levels in urine. Participants will receive finerenone adjusted for age and body weight alongside their current ACEI or ARB therapy. The treatment period lasts up to 18 months, followed by one month of follow-up. During this time, patients will attend at least 12 visits if newly starting finerenone or at least 8 visits if continuing from a previous study, where various health measurements and tests will be conducted. Throughout the study, researchers will monitor participants blood pressure, heart rate, temperature, height, weight, and kidney function through blood and urine tests. They will also perform physical exams, heart checks using electrocardiograms and echocardiography, and collect information on medication use and any side effects. Safety is a primary focus, with careful tracking of any medical problems that arise during treatment, plus a health check about 30 days after the last dose. The entire participation lasts approximately 19 months.
Actively Recruiting
This research aims to find the right dose of BI 764532 obrixtamig, an antibody-like molecule that may help the immune system fight advanced small cell lung cancer and other neuroendocrine tumors. It includes adults whose cancer has not responded to previous treatments or for whom no standard treatment exists. The study is a multi-center, open-label Phase II trial sponsored by Boehringer Ingelheim. Participants receive BI 764532 as an infusion into a vein. The study has three parts Part 1 randomly assigns participants to one of two doses, while Parts 2 and 3 give all participants the same dose and focus on a specific tumor type called extrapulmonary neuroendocrine carcinoma. Treatment continues as long as participants tolerate it and benefit, with regular visits to the study site. The first visits include an overnight stay for safety monitoring. During the study, doctors monitor participants safety, side effects, and overall health through regular assessments. They measure tumor response and track treatment-emergent adverse events for up to 23 to 27 months, depending on the study part. Quality of life and survival outcomes are also recorded. The total number of visits depends on treatment response and tolerance, with ongoing evaluation until study completion.
Actively Recruiting
Researchers are investigating metabolomic profiles to predict how patients with locally advanced rectal cancer respond to total neoadjuvant therapy TNT, which includes chemotherapy and radiation before surgery. This study also aims to identify metabolites linked to treatment side effects like radiation proctitis. Metabolomics, which examines small molecules related to biological functions, may help develop precise tools to forecast treatment success and toxicity. The study involves collecting blood, urine, tissue, and fecal samples from participants at different stages before, during, and after chemoradiotherapy. These samples will be analyzed using liquid chromatography-mass spectrometry LC-MS to identify metabolites associated with treatment response and side effects. Researchers will assess tumor shrinkage and pathological response, as well as radiation proctitis severity using established clinical criteria. Participants will be closely monitored throughout the study, with assessments including metabolomic profiling and clinical evaluations up to six months after radiotherapy or until surgical resection. The primary outcome is the ability of metabolomic profiles to predict complete treatment response. Secondary outcomes include tracking severe treatment-related toxicities. This comprehensive approach aims to improve personalized care for rectal cancer patients by identifying predictive biomarkers.
Actively Recruiting
Researchers are evaluating the Lupus Low Disease Activity State LLDAS in patients with Systemic Lupus Erythematosus SLE, a complex autoimmune disease affecting multiple organs and causing serious health problems. The study aims to see if achieving LLDAS is linked to better outcomes, including less organ damage, as traditional remission is rare and difficult to measure in lupus patients. The study is international and multi-center, led by the Asia Pacific Lupus Collaboration and sponsored by Monash University. Patients with SLE will be followed for approximately five years. During this time, researchers will collect regular data on disease activity and treatment to assess whether patients meet the LLDAS criteria. Annual assessments will also record lupus-related organ damage using the SLICC-ACR Damage Index and quality of life using the Short Form 36 version 2. At the end of the study, the researchers will evaluate if sustained LLDAS protects against organ damage. Participants will have their clinical and treatment data monitored regularly over several years. The study will measure outcomes including organ damage progression, quality of life, and mortality. These long-term assessments will help determine whether LLDAS is a useful target in managing lupus. The total participation time is about five to ten years, allowing detailed tracking of disease impact and patient well-being.